Index Entries - Covid Index

1828 Results

Title	IS Publication Date
Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection	March 5, 2021
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19	August 14, 2020
Rochelle Walensky on the risk of COVID-19 vaccines for 12-17 year olds	June 24, 2021
Role of hydroxychloroquine in multidrug treatment of COVID-19	September 24, 2021
Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study	February 16, 2021
Rush to Use Ventilators Killed Thousands of COVID Patients	September 18, 2024
S2 subunit of SARS-nCoV-2 interacts with tumor suppressor protein p53 and BRCA: an in silico study	June 30, 2020
Sacrifice: How the Deadliest Vaccine in History Targeted the Most Vulnerable	February 18, 2025
Safe and Effective: A Second Opinion	September 28, 2022
Safe Nanoparticles: Are We There Yet?	December 31, 2020
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months	November 4, 2021
Safety and Health Guidance: COVID-19 Infection Prevention for Logistics Employers and Employees	October 27, 2020
Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data	February 26, 2024
Safety of COVID-19 Vaccines: Spotlight on Neurological Complications	August 29, 2022
Safety of mRNA Vaccines Administered During the First Twenty-Four Months of the International COVID-19 Vaccination Program	April 10, 2023
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting	September 16, 2021
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry	December 31, 2021
Safety Profiles of mRNA COVID-19 Vaccines Using World Health Organization Global Scale Database (VigiBase): A Latent Class Analysis	December 15, 2022
Safety Signals for COVID Vaccines Are Loud and Clear. Why Is Nobody Listening?	September 29, 2021
SARS-CoV-2 and the Vaccination Hype	January 17, 2022
SARS-CoV-2 antibodies persist up to 12 months after natural infection in healthy employees working in non-medical contact-intensive professions	November 24, 2022
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy	April 27, 2021
SARS-CoV-2 B.1.1.529 (Omicron) Variant — United States, December 1–8, 2021	December 17, 2021
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19	September 8, 2020
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor	March 5, 2020
SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity	June 4, 2021
SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans	May 24, 2021
SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19	March 22, 2021
SARS-CoV-2 Is an Unrestricted Bioweapon: A Truth Revealed through Uncovering a Large-Scale, Organized Scientific Fraud	October 8, 2020
SARS-CoV-2 mass vaccination: Urgent questions on vaccine safety that demand answers from international health agencies, regulatory authorities, governments and vaccine developers	May 20, 2021
SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis	August 30, 2021
SARS-COV-2 mRNA Vaccine (BNT162, PF-07302048) — 2.6.4 Summary statement of the pharmacokinetic study
SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels	September 17, 2020
SARS-CoV-2 Proteins Interact with Alpha Synuclein and Induce Lewy Body-like Pathology In Vitro	March 21, 2022
SARS-CoV-2 re-infection risk in Austria	February 13, 2021
SARS-CoV-2 RNA reverse-transcribed and integrated into the human genome	December 13, 2020
SARS-CoV-2 S1 Protein Persistence in SARS-CoV-2 Negative Post-Vaccination Individuals with Long COVID/ PASC-Like Symptoms	July 12, 2022
SARS-CoV-2 Spike Glycoprotein S1 Induces Neuroinflammation in BV-2 Microglia	October 28, 2021
SARS-CoV-2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID-19 vaccination	January 17, 2023
SARS-CoV-2 Spike Protein Accumulation in the Skull-Meninges-Brain Axis: Potential Implications for Long-Term Neurological Complications in post-COVID-19	April 5, 2023
SARS-CoV-2 spike protein alone may cause lung damage	April 27, 2021
SARS-CoV-2 Spike Protein and Its Receptor Binding Domain Promote a Proinflammatory Activation Profile on Human Dendritic Cells	November 23, 2021
SARS-CoV-2 Spike Protein and Lung Vascular Cells	December 30, 2020
SARS-CoV-2 Spike Protein Disrupts Blood–Brain Barrier Integrity via RhoA Activation	October 23, 2021
SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines	January 11, 2021
SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2	March 31, 2021
SARS-CoV-2 spike protein induces abnormal inflammatory blood clots neutralized by fibrin immunotherapy	October 13, 2021
SARS-CoV-2 spike protein induces cognitive deficit and anxiety-like behavior in mouse via non-cell autonomous hippocampal neuronal death	March 31, 2022
SARS-CoV-2 Spike Protein Induces Degradation of Junctional Proteins That Maintain Endothelial Barrier Integrity	June 11, 2021
SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects

Page 28 of 37